United Therapeutics Corporation

United Therapeutics is headquartered in the United States and generates most revenue there, with commercial distribution centered on U.S. specialty pharmacy and hospital channels. It also sells selected products internationally, including Nebulized Tyvaso, Remodulin, and Unituxin in markets across Europe, Asia, the Middle East, Latin America, Canada, and Japan. Manufacturing and development activities are concentrated in the U.S., including facilities and planned capacity in North Carolina, Virginia, Minnesota, and Texas. Geography matters because the business is highly dependent on U.S. reimbursement and regulatory access, while international sales depend on local distributors and approvals.

The company is concentrated in treprostinil-based therapies, so any slowdown in Tyvaso, Remodulin, or Orenitram can materially affect revenue. It also faces competition, pricing pressure, reimbursement risk, and patent challenges in a market where large pharmaceutical companies and new entrants can erode share. Operationally, it depends on third-party manufacturers, distributors, and regulators, so supply disruptions or approval delays can affect product availability and launches.